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Abstract
Background: The critical role of the androgen receptor (AR) in the development of prostate
cancer is well recognized. The transcriptional activity of AR is partly regulated by coregulatory
proteins. It has been suggested that these coregulators could also be important in the progression
of prostate cancer. The aim of this study was to identify coregulators whose expression is regulated
by either the androgens and/or by the expression level of AR.
Methods: We used empty vector and AR cDNA-transfected LNCaP cells (LNCaP-pcDNA3.1, and
LNCaP-ARhi, respectively), and grew them for 4 and 24 hours in the presence of
dihydrotestosterone (DHT) at various concentrations. The expression of 25 AR coregulators
(SRC1, TIF2, PIAS1, PIASx, ARIP4, BRCA1, β-catenin, AIB3, AIB1, CBP, STAT1, NCoR1, AES, cyclin D1,
p300, ARA24, LSD1, BAG1L, gelsolin, prohibitin, JMJD2C, JMJD1A, MAK, PAK6 and MAGE11) was then
measured by using real-time quantitative RT-PCR (Q-RT-PCR).
Results: Five of the coregulators (AIB1, CBP, MAK, BRCA1 and β-catenin) showed more than 2-fold
induction and 5 others (cyclin D1, gelsolin, prohibitin, JMJD1A, and JMJD2C) less than 2-fold induction.
Overexpression of AR did not affect the expression of the coregulators alone. However,
overexpression of AR enhanced the DHT-stimulated expression of MAK, BRCA1, AIB1 and CBP and
reduced the level of expression of β-catenin, cyclinD1 and gelsolin.
Conclusion: In conclusion, we identified 5 coactivators whose expression was induced by
androgens suggesting that they could potentiate AR signaling. Overexpression of AR seems to
sensitize cells for low levels of androgens.
Background
Prostate cancer is the most and second most common
male malignancy in the USA, and Europe, respectively
[1,2]. The androgen-dependence of the growth of prostate
cancer has been known for a long time [3]. The impor-
tance of the androgens was recently, once again, demon-
strated in a large randomized study. In the study the use
of finasteride, an inhibitor of 5α-reductase, which con-
verts testosterone into more potent 5α-dihydrotestoster-
one, was used for prevention of prostate cancer [4].
Almost 25% reduction in the prevalence of prostate can-
cer was observed in the treatment compared to a placebo
arm. Due to the androgen dependence, the golden stand-
ard treatment for advanced prostate cancer has been
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tury [5]. The treatment is palliative and although most
patients respond to it, the disease will eventually progress
[6]. Such tumors, emerging during the androgen with-
drawal, are called hormone-refractory ones.
The molecular mechanisms by which prostate cancer cells
become resistant to endocrine therapy remain incom-
pletely known. However, the key role of androgens and
androgen receptor (AR), not just in early development but
also in the progression of prostate cancer has now been
demonstrated [7]. The recent finding on genetic rear-
rangement leading to formation of TMPRSS2:ERG fusion
gene provides a model for molecular mechanisms how
androgens act in promoting the early development of
prostate cancer. Due to the rearrangement, the putative
oncogene ERG becomes androgen regulated [8,9]. It has
now also become apparent that the emergence of hor-
mone-refractory prostate cancer is due to reactivation of
AR-mediated signaling. It has been experimentally shown
that overexpression on AR is required and it is sufficient to
transform the growth of prostate cancer cells from andro-
gen-dependence to -independence [10]. Furthermore, it
has been shown that hormone-refractory tumors overex-
press AR, and one-third of them contains amplification of
the AR gene [11]. Mutations in the coding region of AR
have also been found in antiandrogen treated prostate
cancers [12,13]. And at least some of the mutations alter
the sensitivity of the receptor to other steroid hormones or
anti-androgens, such as 17 β-estradiol (E2) or hydroxy-
flutamide (HF) [14,15].
The transactivation of AR involves several coregulatory
proteins [16,17]. Large number of coregulatory proteins
have already been identified [18-20]. It has been sug-
gested that changes in the expression of the coregulators
may be involved in the development and progression of
prostate cancer [18,21,22]. Since androgens and AR are
known to be important in the prostate cancer tumorigen-
esis, it is possible that they also regulate the expression of
the coregulators.
In order to identify AR coregulators whose expression is
regulated by androgens, we measured the expression of 20
putative coactivators: SRC1 (alias NCOA1 nuclear recep-
tor coactivator 1), TIF2 (alias NCOA2 nuclear receptor
coactivator 2), PIAS1 (protein inhibitor of activated STAT,
1), PIASx (alias PIAS2 protein inhibitor of activated STAT,
2), ARIP4 (alias RAD54L2 RAD54-like 2 (S. cerevisiae)),
BRCA1 (breast cancer 1, early onset), β-catenin (alias
CTNNB1 catenin (cadherin-associated protein), beta 1, 88
kDa), AIB3 (alias NCOA6 nuclear receptor coactivator 6),
AIB1 (alias NCOA3 nuclear receptor coactivator 3), CBP
(alias CREBBP CREB binding protein (Rubinstein-Taybi
syndrome)), STAT1 (signal transducer and activator of
transcription 1, 91 kDa), p300 (alias EP300 E1A binding
protein p300), ARA24 (alias RAN, member RAS oncogene
family), LSD1 (lysine-specific demethylase 1, alias AOF2
amine oxidase (flavin containing) domain 2), BAG1L
(BCL2-associated athanogene, isoform 1L), gelsolin (GSN
(amyloidosis, Finnish type)), JMJD2C (alias JHDM3C/
GASC1 jumonji domain containing 2C), JMJD1A (alias
JHMD2A jumonji domain containing 1A), MAK (male
germ cell-associated kinase), MAGE11 (alias MAGEA11
melanoma antigen family A, 11) and 5 putative corepres-
sors: NCoR1 (nuclear receptor co-repressor 1), AES
(amino-terminal enhancer of split), cyclin D1 (alias
CCND1), prohibitin (PHB) and PAK6 (p21(CDKN1A)-acti-
vated kinase 6) by using quantitative reverse transcrip-
tion-PCR (Q-RT-PCR) in AR positive prostate cancer cell
line LNCaP treated with different concentrations of DHT.
To mimic the common overexpression of AR in hormone-
refractory prostate cancer, we also stable transfected AR to
LNCaP cell line. The LNCaP-ARhi cells express about 10-
folds more AR mRNA and 3 to 4-folds more AR protein
than that of the control (empty vector-transfected cell
line: LNCaP-pcDNA3.1). The cell model was used to study
whether the level of AR has an effect on the mRNA expres-
sion of the coregulators.
Methods
Cell culture protocols and transfections
pcDNA3.1(+) empty expression vector (Invitrogen Inc.,
Carlsbad, CA, USA) and pcDNA3.1(+) inserted with AR
coding region were stable transfected into LNCaP (ATCC,
Manassas, VA, USA) with Lipofectamine-Plus transfection
reagent (Invitrogen Inc.). Transfected clones were selected
with 400 μg/ml geneticin (G418) for 2 weeks. The mRNA
level of AR was examined from purified clones using
Northern blotting and Q-RT-PCR with Light-Cycler
(Roche Inc., Mannheim, Germany). The protein level of
AR was analyzed using Western blotting with anti-AR anti-
body (441, NeoMarkers-Lab Vision Corporation, Fre-
mont, CA, USA). LNCaP-pcDNA3.1 (transfected with
empty pcDNA3.1-vector as a control) and LNCaP-ARhi
(transfected with AR cloned into pcDNA3.1+ vector) cell
lines were cultured according to the ATCC protocol with
the addition of Geneticin 200 μg/ml (Invitrogen Inc.).
LNCaP-ARhi has about 10 times higher mRNA level of AR
and 3 to 4 times higher protein level of AR than that of the
LNCaP-pcDNA3.1 (Figure 1).
LNCaP-pcDNA3.1 and LNCaP-ARhi cells in the end of the
exponential growing phase were divided in 1:4 ratio
plates in RPMI1640 phenol free medium with 5% char-
coal/dextran-treated (CCS) FBS (Hyclone Inc., South
Logan, UT, USA), 1% glutamine (Invitrogen Inc.) and 1%
penicillin-streptomycin (BioWhittaker Inc., Walkersville,
MD, USA) for 4 days. The medium was then changed to
phenol free RPMI1640 including 10% CCS-FBS (HyclonePage 2 of 10
(page number not for citation purposes)
BMC Cancer 2008, 8:219 http://www.biomedcentral.com/1471-2407/8/219Inc.), 1% Glutamine (Invitrogen Inc.), 1% Pest (Invitro-
gen Inc.) and 0, 0.1, 1.0, 10 or 100 nM DHT. The cells
were harvested into TRIZOL reagent (Life Technologies
Inc., Gaithersburg, MD, USA) after 4 h and 24 h, followed
by total RNA isolation according to the manufactures pro-
tocol.
RT-PCR
The cDNA was synthesized with AMV Reverse Tran-
scriptase and oligo(dT)12–18 primer according to the
manufacturer's protocol (Finnzymes, Espoo Finland). The
standards were prepared mixing total RNA from untreated
LNCaP cells and universal RNA (Clontech Laboratories,
Inc., Mountain View, CA, USA) in a ratio of 1:5. After first
strand cDNA synthesis, serial dilutions corresponding to
1000, 200, 40, 8, 1.6, 0.32, 0.064 μg of RNA pool were
prepared and stored in aliquots. The PCR reactions were
performed in LightCycler apparatus (Roche Inc.) using an
LC Fast Start DNA SYBR Green I Kit (Roche Diagnostics,
Mannheim, Germany). The final volume of each reaction
was 20 μl containing 2 μl of cDNA sample (or standard),
4 mM MgCl2 (except for PAK6 (5 mM) and JMJD1A (3
mM)), 0.5 μM each primer, and 1× ready-to-use SYBR
Green I reaction mix including Taq DNA polymerase,
reaction buffer and a deoxynucleotide triphosphate mix.
The cycling conditions were designed according to the
manufacturer's guidelines which are given in additional
file 1: primers' table. The primers were designed for ampli-
fying regions of the mRNAs derived from different exons
to avoid amplification of genomic DNA. The melting
curve analysis with the LightCycler together with 1.5%
agarose gel electrophoresis of the products were used to
ensure that right size product without significant back-
ground was amplified in the reaction. The expression lev-
els of the coregulators were normalized to the expression
levels of TATA-box binding protein (TBP) as previously
described [23].
Western analysis
Cytoplasmatic and nuclear proteins were isolated from
subconfluent cells of LNCaP-ARhi. Proteins were sepa-
rated in 10% SDS-PAGE gel followed by transfer to a
membrane (Immobilon-P, Millipore Corp., Billerica, MA)
using BIORAD transblot® semi-dry transfer cell (Bio-Rad
Laboratories, Inc). After blocking in PBS 0.1% Tween 5%
BSA (or 5% non-fat dry milk), the membranes were incu-
bated with primary antibody (AR: dilution 1: 200 Andro-
gen Receptor Ab-1 (AR441) Neomarkers, Fremont, CA; β-
catenin: dilution 1:2000 BD Transduction Laboratories,
Inc.; MAK: dilution 1:500 MAK antibody (C-term),
ABGENT San Diego, CA; CBP: dilution 1:1000, R&D Sys-
tems, Inc.) over night at +4°C. After washes and incuba-
tion with secondary antibody (DAKO A/S, Denmark) the
bound antibody was visualized on autogradiography film
using Western Blotting Luminol Reagent (Santa Cruz,
Inc.) according to the manufacturer's protocol. Pan-actin
antibody (dilution 1:1000 pan AB-5, clone ACTN05, Neo-
markers, Fremont, CA;) was used as a reference.
Statistical analysis
Grubb's test was used to detect the outlier values in the
repetitive runs for each gene. One-way ANOVA (Paramet-
ric) test with Bonferroni post-test was used to evaluate the
statistical significance of the expression level's changes.
Western blot analysis of AR in empty vector transfected (LNCaP-pcDNA3.1) and AR-cDNA transfected (LNCaP-ARhi) LNCaP cel sFigure 1
Western blot analysis of AR in empty vector transfected (LNCaP-pcDNA3.1) and AR-cDNA transfected (LNCaP-ARhi) 
LNCaP cells. Cells were grown either in the absence or presence of DHT. Nuclear fraction of LNCaP-ARhi shows clearly 
higher AR expression than the control LNCaP-pcDNA3.1. The quantification of the bands by ImageJ is given below the bands.Page 3 of 10
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To identify androgen regulated coregulators, empty vector
transfected LNCaP (LNCaP-pcDNA3.1) was grown in dif-
ferent concentrations of DHT. The total RNA was then col-
lected at two time points (4 h and 24 h). To confirm the
success of the DHT stimulation, the expression of pros-
tate-specific antigen (PSA), known androgen regulated
gene was first measured (Figure 2). PSA was strongly
induced by DHT (p < 0.0001 at 4 h and 24 h).
Next, we screened expression of SRC1, TIF2, PIAS1, PIASx,
ARIP4, BRCA1, β-catenin, AIB3, AIB1, CBP, STAT1,
NCoR1, AES, cyclin D1, p300, ARA24, LSD1 and BAG1L
coregulators in triplicates (three independent Q-RT-PCRs'
runs). Of the coregulators, PIASx (p = 0.0601 at 4 h and p
= 0.6488 at 24 h), BRCA1 (p = 0.4172 at 4 h and p =
0.0377 at 24 h), β-catenin (p = 0.0272 at 4 h and p =
0.4158 at 24 h), AIB3 (p = 0.0690 at 4 h and p = 0.1455
at 24 h), AIB1 (p = 0.0401 at 4 h and p = 0.2541 at 24 h),
CBP (p = 0.0184 at 4 h and p = 0.0588 at 24 h), cyclin D1
(p = 0.2039 at 4 h and p = 0.4432 at 24 h), ARA24 (p =
0.0220 at 4 h and p = 0.2502 at 24 h) and BAG1L (p =
0.0359 at 4 h and p = 0.3981 at 24 h), showed dose
dependent response to androgens, whereas SRC1, TIF2,
PIAS1, ARIP4, STAT1, NCoR1, AES, p300 and LSD1 did
not.
PIASx, BRCA1, β-catenin, AIB3, AIB1, CBP, cyclin D1,
ARA24 and BAG1L were selected for additional Q-RT-PCR
runs in triplicates. In addition, expression of gelsolin, pro-
hibitin, JMJD2C, JMJD1A, MAK, PAK6 and MAGE11 was
measured in triplicates. Figures 3 and 4 show the expres-
sion pattern of these 16 coregulators upon DHT stimula-
tion. The genes that showed significant dose dependent
expression were AIB1, CBP, MAK, BRCA1, β-catenin, cyclin
D1, gelsolin, prohibitin, JMJD1A, and JMJD2C. Table 1 indi-
cates the p-values of the sixteen genes. Gelsolin showed
reduced and increased expression at 4 and 24 hour time
points, respectively. Others exhibited an androgen-
dependent increase in the expression of the mRNAs. How-
ever, only AIB1, CBP, MAK, BRCA1, and β-catenin showed
more than 2-folds induction after stimulation with DHT.
In order to evaluate the effect of the level of AR expression
on the expression of the coregulators, we utilized LNCaP-
based overexpression model (LNCaP-ARhi). The PSA
response in the LNCaP-ARhi cell line at 24 hours was sig-
nificantly (p < 0.0001) stronger than in the empty vector
transfected cell line (LNCaP-pcDNA3.1) (Figure 2). PSA
Expression of PSA in LNCaP-pcDNA3.1 and LNCaP-ARhi according to Q-RT-PCRFigure 2
Expression of PSA in LNCaP-pcDNA3.1 and LNCaP-ARhi according to Q-RT-PCR. The cells were cultured in presence of 
DHT at different concentrations. After 4 and 24 hours, the cells were collected and expression of PSA and TBP mRNA was 
measured in triplicates by Q-RT-PCR. The bars and whiskers represent mean + S.E.M. of PSA/TBP values normalized against the 
0 M of each time point.Page 4 of 10
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in the LNCaP-ARhi, whereas the stimulation was evident
in 10 nM in the LNCaP-pcDNA3.1.
None of the coregulators showed significant alterations in
the expression in 0 M DHT between the LNCaP-
pcDNA3.1 and LNCaP-ARhi. However, induction of
expression in lower concentrations of DHT in LNCaP-
ARhi compared to LNCaP-pcDNA3.1 was found in MAK,
CBP, AIB1, and BRCA1. In contrast, the androgen regula-
tion of β-catenin, cyclin D1 and gelsolin, which was appar-
ent in LNCaP-pcDNA3.1 at 24 h was less strong in LNCaP-
ARhi (Figures 3 and 4).
Western blot analyses of β-catenin, CBP and MAK were in
concordance with the Q-RT-PCR results (see additional
file 2: WB analysis).
Discussion
We systematically studied the androgen regulation of the
expression of twenty-five AR coregulators. 5 (20%) coreg-
ultators showed statistically significant over 2-fold induc-
tion by DHT. These were AIB1, CBP, MAK, BRCA1 and β-
catenin. In addition, expression of five (20%) other coreg-
ulators (cyclin D1, gelsolin, prohibitin, JMJD1A, and
JMJD2C) was significantly, but less than 2-fold, induced
by androgens.
AIB1 (Amplified in Breast Cancer 1) encodes for a well
characterized protein with histone acetyltransferase activ-
ity. It is thought to be a nuclear receptor coactivator that
interacts with various nuclear hormone receptors enhanc-
ing their transcriptional activity in a hormone dependent
fashion. It is a member of the p160/steroid receptor coac-
tivator (SRC) family and recruits p300/CBP-associated
factor, with histone acetylation activity, and CBP (CREB
binding protein) as a part of the transcription multisubu-
nit coactivation complex [19,24]. AIB1 has been found to
be amplified in about 10% of breast cancers [25]. Previous
studies have indicated that estrogens might have a sup-
pressive role in respect to the expression of AIB1 [26,27].
Here we found that at 4 hours time point AIB1 is nearly 2-
fold induced by any concentration of DHT while at 24
hours time point a 4-fold induction was observed. The
highest induction was at 1 nM DHT while at 10 nM the
expression was declined. We used web-based TESS (Tran-
scription Element Search Software) program and TRANS-
FAC database [28] to search for canonical binding sites for
AR in the 2 kb upstream the transcription start site (TSS)
of AIB1. The program identified several glucocorticoid
receptor (GR) responsive elements (GREs) and two puta-
tive androgen responsive elements (AREs) at -527 and at -
1291 bp from the TSS.
Similarly to AIB1, CBP was nearly 2-folds induced at 4
hours time point by any concentration of DHT while at 24
hours time point a 4-folds induction can be observed,
although such induction can be seen also in 10 nM DHT
concentrated media. In contrast with our results, Comuzzi
et al. have suggested that CBP expression is down-regu-
lated after treating LNCaP cells with synthetic androgen
methyltrienolone (R1881) for 48 hours at concentrations
of 0.01 nM and 1 nM [29].
MAK (Male Germ Cell-Associated Kinase) is a recently
identified AR coactivator [30] that initially has been
found to be strongly androgen-regulated in mice kidney
[31]. In addition, it has previously been demonstrated
that MAK is transcriptionally induced by DHT in LNCaP
cells showing 9-fold induction by 10 nM DHT at 24 hours
[32]. This is confirmed by our finding of 6.5-fold induc-
tion at 24 hours time point by 10 nM DHT. MAK has been
found to be associated with AR and being corecruited in
the transcriptional complex enhancing AR activity. Fur-
thermore the modulation of its expression strongly alters
the vitality of the cells affecting AR pathway mediated sig-
naling [30]. Jia et al. have shown that MAK promoter is a
direct target of AR and identified putative ARE sites within
the promoter of MAK (about -3500 bp from the TSS), and
that AR is recruited to the MAK promoter after DHT stim-
ulation according to chromatin immunoprecipitation
(ChIP) analysis [33]. Altogether the data indicates that the
expression of MAK is regulated by androgens and since it
functions as an AR co-activator, it forms a putative feed-
back loop augmenting the effects of androgens.
Table 1: p-values of the One-way ANOVA (Parametric) test
Gene LNCaP-pcDNA3.1 LNCaP-ARhi
4 h 24 h 4 h 24 h
AIB1 0.0019 < 0.0001 0.0023 < 0.0001
CBP 0.0478 0.0103 0.0035 0.0205
MAK 0.1385 0.0014 0.0090 0.1625
BRCA1 0.0007 < 0.0001 0.0022 < 0.0001
B-catenin 0.0336 < 0.0001 < 0.0001 < 0.0001
Cyclin D1 0.0094 0.0094 0.6382 0.4697
Gelsolin 0.0016 < 0.0001 0.0029 0.4211
Prohibitin 0.0291 0.0084 0.0114 0.0053
JMJD1A 0.0276 0.0009 < 0.0001 0.4592
JMJD2C 0.0588 0.0064 0.0259 0.6450
BAG-1L 0.0029 0.1467 0.0244 0.0150
PIASx 0.9371 0.8551 0.8224 0.7616
PAK6 0.1075 0.4876 0.3359 0.6410
MAGE11 0.7256 0.5952 0.6438 0.6014
AIB3 < 0.0001 0.0135 < 0.0001 0.3818
ARA24 0.0016 0.0276 0.0007 0.0013
p-values of the 16 genes were measured in triplicate in the second 
round analysis.Page 5 of 10
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The expression of AIB1, CBP, MAK, BRCA1, β-catenin, cyclin D1, gelsolin and prohibitin in LNCaP-pcDNA3.1 and LNCaP-ARhi at 4 and 24 hours according to Q-RT-PCFigure 3
The expression of AIB1, CBP, MAK, BRCA1, β-catenin, cyclin D1, gelsolin and prohibitin in LNCaP-pcDNA3.1 and LNCaP-ARhi at 4 
and 24 hours according to Q-RT-PCR. The measurements were done in triplicates. The bars and whiskers represent mean + 
S.E.M. of each gene against the TBP, normalized against the 0 M of each time point. p-values are given in Table 1.
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The expression of JMJD1A, JMJD2C, BAG1L, PIASx, PAK6, MAGE11, AIB3, and ARA24 in LNCaP-pcDNA31 and LNCaP-ARhi at 4 and 24 hours according to Q-RT-PCRFigure 4
The expression of JMJD1A, JMJD2C, BAG1L, PIASx, PAK6, MAGE11, AIB3, and ARA24 in LNCaP-pcDNA3.1 and LNCaP-ARhi at 4 
and 24 hours according to Q-RT-PCR. The measurements were done in triplicates. The bars and whiskers represent mean + 
S.E.M. of each gene against the TBP, normalized against the 0 M of each time point. p-values are given in Table 1.
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breast cancer since mutations in this gene are responsible
of at least 40% of inherited breast cancers and more than
80% of inherited ovarian cancers [34,35]. BRCA1 is also
an AR coactivator that has been demonstrated to enhance
AR transactivation in prostate and breast cancer cell lines
with a synergistic effect with other p160 coactivators [36].
Our data shows an androgen-mediated induction of the
expression of BRCA1. It has previously been demon-
strated that BRCA1 is an estrogen induced gene in breast
and ovarian cancer cells [37,38].
β-catenin is an adherens junction protein with altered
expression in various tumor types. Its fundamental role as
a multifunctional oncoprotein has been established [39].
The gene encodes for a protein that interacts with AR in
close proximity with p160 coactivator family and it is
thought to be important for the formation of the AR tran-
scription complex [40,41]. There is some evidence that AR
could also have an important role as a scaffolding protein
in β-catenin translocation from the cytoplasm into the
nucleus [42-44]. β-catenin has been shown to augment
AR transcriptional function in a ligand-dependent fashion
[43,45]. Here we show that β-catenin is induced up to 2.5-
folds at 24 hours time point, already at a concentration of
0.1 nM of DHT. The induction reaches then the 3-folds
and declines at 2-folds at 100 nM showing a significant
androgen regulation.
In addition to the above mentioned coregulators, cyclin
D1, gelsolin, prohibitin, JMJD1A and JMJD2C showed a sig-
nificant dose dependent effect in their expression level
mainly at 24 hours time point. However, the induction
was very mild, less than 2-fold, suggesting either only
weak androgen effect or secondary mechanisms for the
induction.
It has been demonstrated that AR is commonly overex-
pressed in hormone-refractory prostate cancer [11,46,47].
In addition, it has been shown that the overexpression is
capable to transform androgen dependent growth of pros-
tate cancer cell to independence [9]. To study the effect of
AR overexpression, we stable transfected AR to LNCaP cell
line leading to 3 to 4-fold increased expression of AR. The
growth of LNCaP-ARhi was stimulated on lower concen-
trations of androgens than the growth of LNCaP-
pcDNA3.1 (unpublished data). None of the coregulators
were up- or downregulated by the level of AR alone since
there was no significant difference in the expression of the
coregulators at 0 M of DHT. Instead, the overexpression of
AR seems to sensitize cells to androgens. This was evident
e.g. for PSA, which was significantly upregulated more
and in lower concentrations of DHT in LNCaP-ARhi than
in LNCaP-pcDNA3.1 cells. Similarly, the expression of
MAK, CBP, and BRCA1 was increased more in LNCaP-
ARhi than in LNCaP-pcDNA3.1, and, at least, a 10-fold
sensitization was observed. For MAK and CBP this was
apparent in 4 h time point, whereas for BRCA1 at 24 h
time point. Interestingly, the increased expression of AR
did not affect all androgen-regulated coregulators. β-cat-
enin, cyclin D1 and gelsolin, which showed androgen-regu-
lation in LNCaP-pcDNA3.1 at 24 hours were not
regulated by androgens in LNCaP-ARhi. The data suggest
that the AR overexpression has distinct effects on different
target genes. It should be recognized that during the
androgen withdrawal, there are still adrenal androgens
left. For example, the DHT concentration is only partially
depleted [48]. Thus, the genes that are regulated in
reduced DHT concentrations due to AR overexpression
might be important in the progression of prostate cancer
during the hormonal therapy.
The effects of androgens on gene expression were meas-
ured at two time points, 4 h and 24 h. The 4 h time points
represent a time interval where direct effects of androgens
administration should be seen, although the effect can be
mild. On the other hand, also secondary mechanisms can
already be activated at 24 hours time point. All coregula-
tors (AIB1, CBP, MAK, BRCA1, β-catenin) that were
induced more than 2-fold by DHT, showed the induction
already at 4 time point in one or both cells lines (LNCaP-
pcDNA3.1 and LNCaP-ARhi) suggesting direct regulation.
Whereas, coregulators with lower-level of induction
showed the effect variably in 4 and 24 hour points, which
may also suggest secondary mechanisms of androgen reg-
ulation.
Conclusion
In conclusion, by systematic measurement of 25 AR coreg-
ulators, we identified 5 coregulators whose expression
seems to be significantly androgen-regulated indicating
that they could be a part of positive feedback mechanisms
potentiating the AR signaling. Overexpression of AR
seems to sensitize cells in terms of androgen regulation
but the effect is gene-specific since not all androgen-regu-
lated genes were up-regulated in AR overexpressing
model.
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